Franklin Resources Inc I Mab Transaction History

Franklin Resources Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $34,141 - $105,062	-8,514 Reduced 1.9%	439,809 $1.76 Million
Q2 2022 Aug 11, 2022	BUY	$8.27 - $18.43 $1.59 Million - $3.55 Million	192,734 Added 75.41%	448,323 $5.07 Million
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $2,721 - $10,183	217 Added 0.08%	255,589 $4.15 Million
Q4 2021 Feb 11, 2022	BUY	$45.28 - $74.5 $63,075 - $103,778	1,393 Added 0.55%	255,372 $12.1 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $1.01 Million - $1.5 Million	17,712 Added 7.5%	253,979 $18.4 Million

Q2 2021 Aug 13, 2021	SELL	$47.86 - $83.95 $2.41 Million - $4.23 Million	-50,405 Reduced 17.58%	236,267 $19.8 Million
Q1 2021 May 13, 2021	BUY	$44.38 - $63.97 $11.2 Million - $16.1 Million	251,706 Added 719.86%	286,672 $13.9 Million
Q1 2020 May 13, 2020	BUY	$10.63 - $15.37 $371,688 - $537,427	34,966 New	34,966 $455,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.